Valuation: Haleon plc

Market Cap 30.36B 39.77B 36.22B 33.38B 56.96B 3,683B 59.86B 406B 161B 2,011B 149B 146B 6,312B P/E 2026 *
18.1x
P/E 2027 * 15.9x
Enterprise Value 37.5B 49.12B 44.74B 41.22B 70.35B 4,548B 73.93B 502B 199B 2,484B 184B 180B 7,797B EV / Sales 2026 *
3.32x
EV / Sales 2027 * 3.17x
Free-Float
98.3%
Yield 2026 *
2.33%
Yield 2027 * 2.56%
1 day+0.99%
1 week+0.15%
Current month+8.11%
1 month-7.33%
3 months-4.90%
6 months+0.88%
Current year-7.87%
1 week 338.27
Extreme 338.27
351.6
1 month 310.5
Extreme 310.5
384.1
Current year 310.5
Extreme 310.5
433.6
1 year 310.5
Extreme 310.5
433.6
3 years 274.4
Extreme 274.4
433.6
5 years 241.17
Extreme 241.1735
433.6
10 years 241.17
Extreme 241.1735
433.6
Manager TitleAgeSince
Chief Executive Officer 59 2021-07-21
Director of Finance/CFO 58 2024-10-31
Chief Tech/Sci/R&D Officer 63 2025-07-31
Director TitleAgeSince
Director/Board Member 59 2022-05-22
Chairman 71 2025-12-31
Director/Board Member 59 2022-07-17
Date Insider Type Main position Quantity % Market Cap. Importance
10/30/26 Buy

Director

7,670 0.0001%
9/22/26 Buy 2,139 0.0000%
9/22/26 Buy 12,209 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+0.99%+0.15%-8.46%+5.60% 39.77B
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average +0.40%-4.26%+21.67%+68.64% 411B
Weighted average by Cap. +0.31%-5.14%+25.69%+87.08%

Financials

2026 *2027 *
Net sales 11.29B 14.79B 13.47B 12.42B 21.19B 1,370B 22.27B 151B 60.06B 748B 55.5B 54.33B 2,348B 11.66B 15.28B 13.92B 12.82B 21.88B 1,415B 23B 156B 62.03B 773B 57.33B 56.12B 2,425B
Net income 1.67B 2.19B 1.99B 1.84B 3.13B 203B 3.29B 22.35B 8.88B 111B 8.21B 8.04B 347B 1.83B 2.4B 2.18B 2.01B 3.43B 222B 3.61B 24.5B 9.74B 121B 9B 8.81B 381B
Net Debt 7.14B 9.35B 8.52B 7.85B 13.39B 866B 14.08B 95.52B 37.96B 473B 35.09B 34.35B 1,484B 6.67B 8.73B 7.95B 7.33B 12.51B 809B 13.15B 89.21B 35.46B 442B 32.77B 32.08B 1,386B
Projected Income Statement - Annual - Haleon plc
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (31.4%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - pain relief medicines (23.2%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - respiratory medicines (17%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (15.3%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.; - medicines for digestive health (8.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - other (4.2%). Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.6%), North America (35.1%), and Asia/Pacific (23.3%).
Employees
24,535
Date Price Change Volume
26-11-20 GBX 345.30 +0.99% 29,340,891
26-11-19 GBX 341.90 -0.38% 20,131,653
26-11-18 GBX 343.20 +0.26% 22,330,183
26-11-17 GBX 342.30 -1.27% 28,429,350
26-11-16 GBX 346.70 +0.55% 38,222,705
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Haleon plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.453GBP
Average target price
3.776GBP
Spread / Average Target
+9.34%